Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296331 | 1.00 | NAAA (0.55) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1297087 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1296514 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1297386 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1297435 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL22361227 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1296979 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1296572 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1296678 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR | |
| SCHEMBL1296423 | 0.98 | NAAA (0.59) | NAAAEPHX1EPHX2PPARGTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115485260-A | Processes related to the formation of aryl cyclopropyl carboxylic acids | 科迪华农业科技有限责任公司 | 2022-12-16 | — | — | CN | claimed |
| CN-116194144-A | Prodrugs of phosphoramide nucleotide analogs and pharmaceutical uses thereof | 吉利德科学公司 | 2023-05-30 | — | — | CN | disclosed |
| CN-115485260-A | Processes related to the formation of aryl cyclopropyl carboxylic acids | 科迪华农业科技有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115485260-A | Processes related to the formation of aryl cyclopropyl carboxylic acids | 科迪华农业科技有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| CN-115485260-A | Processes related to the formation of aryl cyclopropyl carboxylic acids | 科迪华农业科技有限责任公司 | 2022-12-16 | — | — | CN | disclosed |
| US-8822724-B2 | Method for producing carboxylic acid amide | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| EP-2486014-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-31 | — | — | EP | disclosed |
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2486030-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2599769-A1 | METHOD FOR PRODUCING CARBOXYLIC ACID AMIDE | Sumitomo Chemical Company Limited (JP) | 2013-06-05 | — | — | EP | disclosed |
| EP-2486014-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20110251204-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-13 | — | — | US | disclosed |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-06 | — | — | US | disclosed |
| WO-2011044195-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011044212-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| CN-101506142-A | Process for production of trans-2,2-dimethyl- 3-formylcyclopropane carboxylic acid ester | SUMITOMO CHEMICAL CO (JP) | 2009-08-12 | — | — | CN | disclosed |
| CN-100341842-C | Process for production of formylcyclopropanecarboxylic ester compound | SUMITOMO CHEMICAL CO (JP) | 2007-10-10 | — | — | CN | disclosed |
| CN-1668570-A | Process for producing formylcyclopropanecarboxylic acid ester compound | SUMITOMO CHEMICAL CO (JP) | 2005-09-14 | — | — | CN | disclosed |
| EP-1517881-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | Syngenta Participations AG (CH) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004002943-A1 | 4-(3,3-DIHALO-ALLYLOXY)PHENOXY ALKYL DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2004-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251204-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | NAAA 3710/4885EPHX1 2758/4885EPHX2 3069/4885 |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | NAAA 3710/4885EPHX1 2758/4885EPHX2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.